This Phase II trial tests the safety and potential benefits of AZD6234 for people with overweight or obesity and Type 2 Diabetes already using a GLP-1 receptor agonist. The goal is to see whether AZD6234 can support better weight and blood sugar control. Participants will continue their current treatment while also receiving the study drug or a placebo.
Eligibility:
• Ages 18–75
• Diagnosed with Type 2 Diabetes
• Currently using a GLP-1 medication and not using insulin
